23andMe (ME) Stock Price, News & Analysis

Company Overview

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $0.60 to $1.10
• 50-Day Range: $0.50 to $0.50
• 52-Week Range: $0.53 to $9.57
• Volume: 29.28 million shs
• Average Volume: 1.57 million shs
• Market Capitalization: $13.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ME Stock Analysis - Frequently Asked Questions

How were 23andMe's earnings last quarter?

23andMe Holding Co. (NASDAQ:ME) announced its earnings results on Tuesday, January, 28th. The company reported ($1.02) earnings per share (EPS) for the quarter. 23andMe had a negative trailing twelve-month return on equity of 170.07% and a negative net margin of 183.39%.

When did 23andMe's stock split?

23andMe shares reverse split before market open on Wednesday, October 16th 2024.The 1-20 reverse split was announced on Friday, October 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of 23andMe own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 23andMe investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 1/28/2025
• Today: 9/22/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ME
• CIK: 1804591
• Web: vgacquisition.com
• Phone: 650-938-6300
• Fax: N/A
• Employees: 770
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): ($15.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$666.70 million
• Net Margins: -183.39%
• Pretax Margin: -186.76%
• Return on Equity: -170.07%
• Return on Assets: -62.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.05
• Quick Ratio: 0.91

Sales & Book Value

• Annual Sales: $208.78 million
• Price / Sales: 0.06
• Cash Flow: $0.54 per share
• Price / Cash Flow: 0.93
• Book Value: $2.34 per share
• Price / Book: 0.21

Miscellaneous

• Outstanding Shares: 26,827,000
• Free Float: 19,766,000
• Market Cap: $13.36 million
• Optionable: Not Optionable
• Beta: 1.19